|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 23-11-10 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 23-07-25 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 2018-08-31 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 2022-12-31 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 2014-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 58 | 2017-09-25 | |
Bruno Schick
BRD | Director/Board Member | - | 2017-09-25 |
Günter von Au
CHM | Chairman | 75 | 2017-09-26 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -1.95% | - | - | 5.73B | ||
| +0.81% | +1.64% | +7.94% | +97.08% | 46.76B | ||
| -1.49% | +1.90% | +71.63% | +130.37% | 37.97B | ||
| -0.32% | +6.32% | -4.67% | +55.19% | 12.14B | ||
| +2.02% | +7.62% | +11.83% | +95.40% | 10.44B | ||
| +4.12% | +1.22% | +37.95% | +119.38% | 9.13B | ||
| -1.55% | +2.14% | +69.81% | -1.57% | 7.65B | ||
| -1.03% | -1.26% | +20.19% | +51.98% | 7.53B | ||
| -0.63% | -1.71% | +60.74% | +282.58% | 6.91B | ||
| +1.50% | +1.38% | +170.00% | +554.28% | 6.31B | ||
| Average | +0.34% | +1.90% | +49.49% | +153.85% | 15.06B | |
| Weighted average by Cap. | +0.14% | +1.94% | +39.24% | +124.81% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Equities
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















